GPATCH2L

Across TCGA pan-cancer cohorts, GPATCH2L RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of GPATCH2L’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where GPATCH2L RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GPATCH2L is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

HNSC, LIHC, and THCA are the cancer types where GPATCH2L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GPATCH2L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	II,III,IV	+0.753	<.001	11	view →
LIHC	Female	II,III,IV	+0.687	<.001	8	view →
THCA	All	II,III,IV	−0.612	<.001	8	view →
BRCA	Female	All	−0.304	<.001	6	view →
CHOL	Male	All	+1.803	<.001	5	view →
UCEC	All	All	−0.430	.024	2	view →
LUSC	Male	All	+0.210	.022	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

GPATCH2L–HNSC

Open the HNSC breakdown →